Since many active pharmaceutical ingredients demonstrate poor aqueous solubility and bioavailability, there is a need for nanotherapeutics improving their efficacy. Further, smart drug
delivery devices, the nanocarriers, can be utilized to selectively target compounds (e.g. biologics, small molecules) to their site of action by taking advantage of passive accumulation mechanisms or
highly selective carrier-cell interactions.
Both strategies are explored by our group combining new formulation technologies with our unique patented drug release technology. Our research activities focus on industrial nanotechnology with emphasis on the development, preparation and characterization of nanosized drug delivery systems, from the early feasibility study to medium-scale manufacture.